Omeros (OMER) FCF Margin (2010 - 2026)

Omeros (OMER) posted FCF Margin of 146.63% for Q1 2026, up 23.92% sequentially from 192.72% in Q2 2022.

Omeros (OMER) FCF Margin (2010 - 2026) Analysis & Trends

Omeros has reported FCF Margin for 14 years, with the latest figure at 146.63% in Q1 2026.

  • Quarterly FCF Margin changed N/A year-over-year to 146.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 351.17% (down 57893.0% YoY) and the FY2020 annual result came in at 135.98%, down 8195.0% from the prior year.
  • FCF Margin rose to 146.63% in Q1 2026 per OMER's latest filing, from 192.72% in the prior quarter.
  • Over five years, FCF Margin peaked at 146.63% in Q1 2026 and troughed at 217.17% in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 30.39%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 13.35%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 25.68%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -77,594.17%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 70.82%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 22.62%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -22.35%
10 Omeros 1.24 Bn 1.24 Bn 27.73 Mn 14.39%

Historic Data

Download Data
DateValue
Jun 30, 2026 14.39%
Mar 31, 2026 -146.63%
Jun 30, 2022 -192.72%
Mar 31, 2022 -217.17%
Dec 31, 2021 22.89%
Sep 30, 2021 -79.20%
Jun 30, 2021 -96.03%
Mar 31, 2021 -191.19%
Dec 31, 2020 -173.13%
Sep 30, 2020 -134.08%
Jun 30, 2020 -278.94%
Mar 31, 2020 -39.12%
Dec 31, 2019 -68.92%
Sep 30, 2019 -25.32%
Jun 30, 2019 -62.37%
Mar 31, 2019 -60.29%
Dec 31, 2018 -112.41%
Sep 30, 2018 -802.13%
Jun 30, 2018 -1,879.94%
Mar 31, 2018 -722.86%